Shahrul Mt-Isa

Shahrul Mt-Isa

Auto-generated profile, based on publicly available information

Shahrul Mt-Isa

Biostatistics & Research Decision Sciences (BARDS), MSD Innovation & Development Hub GmbH, Merck Sharp & Dohme, Zürich, 8058, Switzerland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
ARAlicja R. Rudnicka
Alicja R. Rudnicka
SMShahrul Mt-Isa
Shahrul Mt-Isa
COChristopher G. Owen
Christopher G. Owen
DCDerek G. Cook
Derek G. Cook
DADeborah Ashby
Deborah Ashby
Purpose. To quantify the variation in primary open-angle glaucoma (OAG) prevalence with age, gender, race, year of publication, and survey methodology.

9 February 2013 in Thorax
Verified
Journal Article
Open access
PDF file
AHAlex R Horsley
Alex R Horsley
JDJane C. Davies
Jane C. Davies
RGRobert D. Gray
Robert D. Gray
KMKenneth A Macleod
Kenneth A Macleod
JDJackie Donovan
Jackie Donovan
EAEric Wfw Alton
Eric Wfw Alton
Background Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well characterised and clinically relevant outcome measures. Aim To evaluate a range of conventional and novel biomarkers of CF lung disease in a multicentre setting as a contributing study in selecting outcome assays for a clinical trial of CFTR gene therapy. Methods A multicentre observational study of adult and paediatric patients with CF (>10 years) treated for a physician-defined exacerbation of CF pulmonary symptoms. Measurements were performed at commencement and immediately after a course of intravenous antibiotics. Disease activity was assessed using 46 assays across five key domains: symptoms, lung physiology, structural changes on CT, pulmonary and systemic inflammatory markers. Results Statistically significant improvements were seen in forced expiratory volume in 1 s (p<0.001, n=32), lung clearance index (p<0.01, n=32), symptoms (p<0.0001, n=37), CT scores for airway wall thickness (p<0.01, n=31), air trapping (p<0.01, n=30) and large mucus plugs (p=0.0001, n=31), serum C-reactive protein (p<0.0001, n=34), serum interleukin-6 (p<0.0001, n=33) and serum calprotectin (p<0.0001, n=31). Discussion We identify the key biomarkers of inflammation, imaging and physiology that alter alongside symptomatic improvement following treatment of an acute CF exacerbation. These data, in parallel with our study of biomarkers in patients with stable CF, provide important guidance in choosing optimal biomarkers for novel therapies. Further, they highlight that such acute therapy predominantly improves large airway parameters and systemic inflammation, but has less effect on airway inflammation.

13 May 2014 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SMShahrul Mt‐Isa
Shahrul Mt‐Isa
CHChristine E. Hallgreen
Christine E. Hallgreen
NWNan Wang
Nan Wang
TCTorbjörn Callréus
Torbjörn Callréus
GGGeorgy Genov
Georgy Genov
OPOn Behalf Of The Imi‐Protect Benefit–Risk Participants
On Behalf Of The Imi‐Protect Benefit–Risk Participants

11 January 2010 in Quality and Safety in Health Care
Verified
Journal Article
Closed access
PDF file
SMS. E. McDowell
S. E. McDowell
SMShahrul Mt-Isa
Shahrul Mt-Isa
DADeborah Ashby
Deborah Ashby
RFR. E. Ferner
R. E. Ferner
Objective To investigate the overall probability of error in preparing and administering intravenous medicines; to identify at which stage of the process an error is most likely to occur; and to determine the impact of error correction on the error probability. Design Systematic review and random-effects Bayesian conditional independence modelling. Methods Medline and EMBASE were searched for studies on intravenous medicines. The error rates of each stage were extracted. These, expert estimates, and error rates from generic tasks, were used in a Bayesian conditional independence model to find error ‘hot-spots.’ The main outcome measure was the probability of at least one error occurring during intravenous therapy. Results Nine published studies were identified for inclusion in the systematic review and meta-analysis. The overall probability of making at least one error in intravenous therapy was 0.73 (95% credible interval (CrI) 0.54 to 0.90). If error-checking was introduced at each stage of the process, the overall rate fell to 0.22 (95% CrI 0.14 to 0.31). Errors were most likely in the reconstitution step. Removing the reconstitution step by providing preprepared injections would reduce the overall error rate to 0.17 (95% CrI 0.09 to 0.27). Conclusions Intravenous therapy is complex and error-prone. Error-checking at each stage could reduce the error probability. The use of preprepared injections may help by eliminating errors in the reconstitution of drug and diluent. However, it will be important to ensure that benefits are not outweighed by practical disadvantages such as an increase in selection errors.

1 February 2013 in The Lancet
Verified
Journal Article
Closed access
Sarah LambSarah Lamb
Sarah Lamb
SGSimon Gates
Simon Gates
MWMark Williams
Mark Williams
EWEsther M Williamson
Esther M Williamson
SMShahrul Mt-Isa
Shahrul Mt-Isa
MUMartin R Underwood
Martin R Underwood

4 December 2007 in BMJ
Verified
Journal Article
Closed access
PDF file
MUMartin Underwood
Martin Underwood
DADeborah Ashby
Deborah Ashby
PCPamela Cross
Pamela Cross
EHEnid Hennessy
Enid Hennessy
LLLouise Letley
Louise Letley
KWKen Whyte
Ken Whyte
Objective To determine whether older patients with chronic knee pain should be advised to use topical or oral non-steroidal anti-inflammatory drugs (NSAIDs).Design Randomised controlled trial and patient preference study.Setting 26 general practices.Participants People aged ≥50 with knee pain: 282 in randomised trial and 303 in preference study. Interventions Advice to use topical or oral ibuprofen.Primary outcome measures WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, major and minor adverse effects.Results Changes in global WOMAC scores at 12 months were equivalent. In the randomised trial the difference (topical minus oral) was two points (95% confidence interval −2 to 6); in the preference study, it was one point (−4 to 6). There were no differences in major adverse effects in the trial or study. The only significant differences in secondary outcomes were in the randomised trial. The oral group had more respiratory adverse effects (17% v 7%,95% confidence interval for difference −17% to −2%), the change in serum creatinine was 3.7 mmol/l less favourable (0.9 µmol/l to 6.5 µmol/l); and more participants changed treatments because of adverse effects (16% v 1%, −16% to −5%). In the topical group more participants had chronic pain grade III or IV at three months, and more participants changed treatment because of ineffectiveness.Conclusions Advice to use oral or topical preparations has an equivalent effect on knee pain over one year, and there are more minor side effects with oral NSAIDs. Topical NSAIDs may be a useful alternative to oral NSAIDs.Trial registration ISRCTN 79353052.